Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

BACKGROUND: Large trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of adverse kidney and cardiovascular outcomes in patients with heart failure or chronic kidney disease, or with type 2 diabetes and high risk of atherosclerotic cardiovascular disease. None of...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613836/
https://www.ncbi.nlm.nih.gov/pubmed/36351458
http://dx.doi.org/10.1016/S0140-6736(22)02074-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613836/
https://www.ncbi.nlm.nih.gov/pubmed/36351458
http://dx.doi.org/10.1016/S0140-6736(22)02074-8

Ejemplares similares